
According to a large French study, the risk of hospitalization after vaccination with Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine was about five times higher than those who received the Pfizer Inc (NYSE:PFE) / BioNTech SE's (NASDAQ:BNTX) shot.
The researchers reported the findings in JAMA Network Open. The study included nearly 7 million recipients of the two-dose mRNA vaccine from Pfizer/BioNTech and an equal number of similar people who received the one-shot vector-based JNJ vaccine.